SCHEMBL162974

SCHEMBL162974

Nc1c(Br)cccc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PD P11413 1/20 0.61
CASP7 P55210 1/20 0.61
CASP6 P55212 1/20 0.61
PRNP P04156 1/20 0.50
MMP2 P08253 1/20 0.50
ALDH1A1 P00352 5/20 0.48
ALOX15 P16050 1/20 0.48
FABP4 P15090 1/20 0.45
KDM4E B2RXH2 3/20 0.44
NAPRT Q6XQN6 2/20 0.44
GLA P06280 1/20 0.44
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 2/20 0.42
TSHR P16473 1/20 0.42
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42
HPGD P15428 2/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31003730 1.00 G6PD (0.61) G6PDCASP7CASP6PRNPMMP2
SCHEMBL19991850 0.86 ALDH1A1 (0.50) G6PDCASP7CASP6PRNPMMP2
SCHEMBL526919 0.84 G6PD (0.74) G6PDCASP7CASP6MMP2ALDH1A1
SCHEMBL161850 0.83 METAP2 (0.47) G6PDCASP7CASP6PRNPALDH1A1
SCHEMBL28281319 0.81 G6PD (0.71) G6PDCASP7CASP6MMP2ALDH1A1
SCHEMBL30806223 0.81 G6PD (0.71) G6PDCASP7CASP6MMP2ALDH1A1
SCHEMBL1188598 0.81 G6PD (0.39) G6PDCASP7CASP6PRNPALDH1A1
SCHEMBL28000603 0.81 ALDH1A1 (0.42) G6PDCASP7CASP6PRNPMMP2
SCHEMBL15626666 0.80 MAPT (0.58) ALDH1A1GLAMAPTGAAKMT2A
SCHEMBL30453594 0.80 MAPT (0.58) ALDH1A1GLAMAPTGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116482279-A Method for detecting trace polyamine and polypeptide by bromine-labeled mass spectrometry 西安培华学院 2023-07-25 CN claimed
CN-110330455-B Amide derivative, preparation method and application thereof 湖北省生物农药工程研究中心 2023-04-28 CN claimed
CN-109535010-A A kind of preparation method of bromhexine hydrochloride 广州品红制药有限公司 2019-03-29 CN claimed
CN-109111370-A A kind of preparation method of the bromo- 2- aminobenzoic acid of 3,5- bis- 浙江师范大学 2019-01-01 CN claimed
CN-109096135-A A kind of preparation method of the bromo- 2- aminobenzoic acid of ambroxol hydrochloride intermediate 3,5- bis- 浙江师范大学 2018-12-28 CN claimed
CN-108794409-A The preparation method of thio -4 (1H) -one class compounds of -2,3- dihydroquinazolines of 2- 联化科技股份有限公司 2018-11-13 CN claimed
CN-105461723-B Phthalazines simultaneously assimilation compound of [1,2, b] quinazoline 8 and preparation method thereof and the application in antineoplastic 广西师范大学 2017-12-08 CN claimed
CN-106975459-A Modification cotton stem adsorbent for Adsorption pyrazinamide 北京益净环保设备科技有限公司 2017-07-25 CN claimed
CN-106565684-A 6-pyrromonazole substituted quinazoline compound, and derivative, synthetic method and application thereof 南方医科大学 2017-04-19 CN claimed
CN-101768265-A Modified nylon and preparation method thereof UNIV SUZHOU 2010-07-07 CN claimed
WO-2010017405-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2010-02-11 WO claimed
US-12637428-B2 Isoquinoline derivatives as SIK2 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2026-05-26 US disclosed
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 US disclosed
EP-3749325-B1 DREADD ACTUATORS US HEALTH (US) 2026-04-08 EP disclosed
EP-4701783-A1 PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES Chevron Phillips Chemical Company LP (US) 2026-03-04 EP disclosed
WO-1999012908-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1999-03-18 WO disclosed
EP-0892797-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-01-27 EP disclosed
WO-1997030992-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-28 WO disclosed
US-5401745-A Cardiovascular disorders or hypotensive agents MERCK & CO., INC. (US) 1995-03-28 US disclosed
WO-1994021259-A1 QUINAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES MERCK & CO., INC. (US) 1994-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637428-B2 Isoquinoline derivatives as SIK2 inhibitors SIK2, SIK1, SIK3 G6PD 2495/4885CASP7 2710/4885CASP6 2439/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 G6PD 3448/4885CASP7 880/4885CASP6 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.